Literature DB >> 28823082

MiR-3910 Promotes the Growth and Migration of Cancer Cells in the Progression of Hepatocellular Carcinoma.

Lina Cheng1, Hongwei Wang2, Shuangyin Han3.   

Abstract

INTRODUCTION: Previous studies have reported that specific depletion of mammalian sterile-like kinase (MST1) in the mouse liver driven Hepatocellular carcinoma (HCC). However, how the expression of MST1 was regulated in the progression of HCC remains largely unknown.
MATERIALS AND METHODS: The expression of miR-3910 in the HCC tissues and cell lines were examined using q-PCR. The functions of miR-3910 in HCC were examined using MTT assay, Boyden chamber assay and soft agar assay. The effects of miR-3910 on the metastasis of HCC cells were evaluated using the mouse model.
RESULTS: Here, we have shown that miR-3910 regulated the expression of MST1. MiR-3910 was up-regulated in HCC samples and cell lines, and the expression of miR-3910 was induced by the oncogenic RasV12. In the functional study, miR-3910 was found to promote the growth and migration of HCC cells, and knocking down miR-3910 inhibited the metastasis of HCC cells. Mechanically, it was found that miR-3910 activated YAP signaling by targeting MST1.
CONCLUSION: Taken together, this study demonstrated that miR-3910 exerted oncogenic effects on the progression of HCC and suggested that miR-3910 might be a therapeutic target for cancer therapy.

Entities:  

Keywords:  Cell growth and migration; HCC; MST1; MiR-3910; YAP

Mesh:

Substances:

Year:  2017        PMID: 28823082     DOI: 10.1007/s10620-017-4670-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  26 in total

1.  H-ras Inhibits the Hippo Pathway by Promoting Mst1/Mst2 Heterodimerization.

Authors:  Sonali J Rawat; Daniela Araiza-Olivera; Luis E Arias-Romero; Olga Villamar-Cruz; Tatiana Y Prudnikova; Heinrich Roder; Jonathan Chernoff
Journal:  Curr Biol       Date:  2016-05-26       Impact factor: 10.834

2.  Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo.

Authors:  Wei Wei; Mei-Sze Chua; Susan Grepper; Samuel So
Journal:  Int J Cancer       Date:  2010-05-15       Impact factor: 7.396

3.  MicroRNA-199a-5p inhibition enhances the liver repopulation ability of human embryonic stem cell-derived hepatic cells.

Authors:  Selina Möbus; Dakai Yang; Qinggong Yuan; Timo H-W Lüdtke; Asha Balakrishnan; Malte Sgodda; Bhavna Rani; Andreas Kispert; Marcos J Araúzo-Bravo; Arndt Vogel; Michael P Manns; Michael Ott; Tobias Cantz; Amar Deep Sharma
Journal:  J Hepatol       Date:  2014-08-15       Impact factor: 25.083

4.  The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis.

Authors:  Kieran F Harvey; Cathie M Pfleger; Iswar K Hariharan
Journal:  Cell       Date:  2003-08-22       Impact factor: 41.582

5.  The potential role of miRNAs 21 and 199-a in early diagnosis of hepatocellular carcinoma.

Authors:  Khalda Said Amr; Wafaa M Ezzat; Yasser A Elhosary; Abdelfattah E Hegazy; Hoda H Fahim; Refaat R Kamel
Journal:  Gene       Date:  2015-08-22       Impact factor: 3.688

6.  Functional genomics identified a novel protein tyrosine phosphatase receptor type F-mediated growth inhibition in hepatocarcinogenesis.

Authors:  Rabindranath Bera; Chih-Yung Chiou; Ming-Chin Yu; Jei-Ming Peng; Chung-Ru He; Chih-Yun Hsu; Hsiao-Ling Huang; Uda Y Ho; Shi-Ming Lin; Yu-Jr Lin; Sen-Yung Hsieh
Journal:  Hepatology       Date:  2014-04-25       Impact factor: 17.425

7.  Expression and function of microRNA-27b in hepatocellular carcinoma.

Authors:  Shujie He; Jingyuan Zhang; Juan Lin; Cuisheng Zhang; Shijie Sun
Journal:  Mol Med Rep       Date:  2016-02-03       Impact factor: 2.952

8.  The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families.

Authors:  Yoshiki Murakami; Hidenori Toyoda; Masami Tanaka; Masahiko Kuroda; Yoshinori Harada; Fumihiko Matsuda; Atsushi Tajima; Nobuyoshi Kosaka; Takahiro Ochiya; Kunitada Shimotohno
Journal:  PLoS One       Date:  2011-01-24       Impact factor: 3.240

9.  MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway.

Authors:  Xiao Fu; Hongqing Wen; Li Jing; Yujuan Yang; Wenjuan Wang; Xuan Liang; Kejun Nan; Yu Yao; Tao Tian
Journal:  Cancer Sci       Date:  2017-04-19       Impact factor: 6.716

Review 10.  Emerging role of Hpo signaling and YAP in hepatocellular carcinoma.

Authors:  Vicente Valero; Timothy M Pawlik; Robert A Anders
Journal:  J Hepatocell Carcinoma       Date:  2015-06-18
View more
  7 in total

Review 1.  Hippo in Gastric Cancer: From Signalling to Therapy.

Authors:  Lornella Seeneevassen; Pierre Dubus; Caroline Gronnier; Christine Varon
Journal:  Cancers (Basel)       Date:  2022-05-03       Impact factor: 6.575

Review 2.  The Role of MicroRNAs in Hepatocellular Carcinoma.

Authors:  Xin Xu; Yuquan Tao; Liang Shan; Rui Chen; Hongyuan Jiang; Zijun Qian; Feng Cai; Lifang Ma; Yongchun Yu
Journal:  J Cancer       Date:  2018-09-08       Impact factor: 4.207

Review 3.  Analysis of the role of the Hippo pathway in cancer.

Authors:  Yanyan Han
Journal:  J Transl Med       Date:  2019-04-08       Impact factor: 5.531

Review 4.  Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma-A Review.

Authors:  Kyoko Oura; Asahiro Morishita; Tsutomu Masaki
Journal:  Int J Mol Sci       Date:  2020-11-07       Impact factor: 5.923

Review 5.  MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review.

Authors:  Asahiro Morishita; Kyoko Oura; Tomoko Tadokoro; Koji Fujita; Joji Tani; Tsutomu Masaki
Journal:  Cancers (Basel)       Date:  2021-01-29       Impact factor: 6.639

Review 6.  MicroRNAs Regulating Hippo-YAP Signaling in Liver Cancer.

Authors:  Na-Hyun Lee; So Jung Kim; Jeongeun Hyun
Journal:  Biomedicines       Date:  2021-03-30

7.  miR-103 promotes the metastasis and EMT of hepatocellular carcinoma by directly inhibiting LATS2.

Authors:  Li-Li Han; Xiao-Ran Yin; Shu-Qun Zhang
Journal:  Int J Oncol       Date:  2018-10-01       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.